The cooperative function of arginine residues in the Prototype Foamy Virus Gag C-terminus mediates viral and cellular RNA encapsidation

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Hamann, Martin V ^a,b   Müllers, Erik ^a,b,e   Reh, Juliane ^a,b   Stanke, Nicole ^a,b   Effantin, Gregory ^c,d   Weissenhorn, Winfried ^c,d   Lindemann, Dirk ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c UNIV GRENOBLE ALPES   (France)

^d CNRS   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Assembly; Foamy virus; Gag; RNA packaging

Indexed keywords

ARGININE; GAG PROTEIN; RNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN PROTEIN INTERACTION; RNA ANALYSIS; RNA ENCAPSIDATION; RNA PACKAGING; RNA STRUCTURE; SPUMAVIRUS; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS PARTICLE; AMINO ACID SUBSTITUTION; CELL LINE; GENE DELETION; GENETICS; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; VIRUS ASSEMBLY;

HUMAN SPUMARETROVIRUS; MIRIDAE;

AMINO ACID SUBSTITUTION; ARGININE; CELL LINE; GENE PRODUCTS, GAG; HUMANS; MUTATION, MISSENSE; RNA; SEQUENCE DELETION; SPUMAVIRUS; VIRUS ASSEMBLY;

EID: 84934906249     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0087-7     Document Type: Article

References (57)

1. Goff S: Retroviridae. In Fields Virology. Volume 2. 6th edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wikins, a Wolters Kluwer business; 2013.
2. D'Souza V, Summers MF: How retroviruses select their genomes. Nat Rev Microbiol 2005, 3:643-655.
3. Jouvenet N, Laine S, Pessel-Vivares L, Mougel M: Cell biology of retroviral RNA packaging. RNA Biol 2011, 8:572-580.
4. Lu K, Heng X, Summers MF: Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol 2011, 410:609-633.
5. Rein A, Datta SA, Jones CP, Musier-Forsyth K: Diverse interactions of retroviral Gag proteins with RNAs. Trends Biochem Sci 2011, 36:373-380.
6. Schwartz MD, Fiore D, Panganiban AT: Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication. J Virol 1997, 71:9295-9305.
7. Johnson SF, Telesnitsky A: Retroviral RNA dimerization and packaging: the what, how, when, where, and why. PLoS Pathog 2010, 6:e1001007.
8. Rulli SJ Jr, Hibbert CS, Mirro J, Pederson T, Biswal S, Rein A: Selective and nonselective packaging of cellular RNAs in retrovirus particles. J Virol 2007, 81:6623-6631.
9. Jewell NA, Mansky LM: In the beginning: genome recognition, RNA encapsidation and the initiation of complex retrovirus assembly. J Gen Virol 2000, 81:1889-1899.
10. Glebe D, Bremer CM: The molecular virology of hepatitis B virus. Semin Liver Dis 2013, 33:103-112.
11. Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D: Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 1990, 344:552-555.
12. Bartenschlager R, Junker-Niepmann M, Schaller H: The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol 1990, 64:5324-5332.
13. Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A: Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J Virol 2010, 84:7174-7184.
14. Lan YT, Li J, Liao W, Ou J: Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication. Virology 1999, 259:342-348.
15. Rethwilm A, Lindemann D: Foamy Viruses. In Fields Virology. Volume 2. 6th edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wikins, a Wolters Kluwer business; 2013:1613-1632.
16. Lindemann D, Pietschmann T, Picard-Maureau M, Berg A, Heinkelein M, Thurow J, Knaus P, Zentgraf H, Rethwilm A: A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity. J Virol 2001, 75:5762-5771.
17. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML: Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 1996, 271:1579-1582.
18. Müllers E: The foamy virus Gag proteins: what makes them different? Viruses 2013, 5:1023-1041.
19. Yu SF, Edelmann K, Strong RK, Moebes A, Rethwilm A, Linial ML: The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains. J Virol 1996, 70:8255-8262.
20. Müllers E, Uhlig T, Stirnnagel K, Fiebig U, Zentgraf H, Lindemann D: Novel functions of prototype foamy virus Gag glycine- arginine-rich boxes in reverse transcription and particle morphogenesis. J Virol 2011, 85:1452-1463.
21. Berkowitz R, Fisher J, Goff SP: RNA packaging. Curr Top Microbiol Immunol 1996, 214:177-218.
22. Stenbak CR, Linial ML: Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression. J Virol 2004, 78:9423-9430.
23. Lee EG, Linial ML: The C terminus of foamy retrovirus Gag contains determinants for encapsidation of Pol protein into virions. J Virol 2008, 82:10803-10810.
24. Linial ML, Eastman SW: Particle assembly and genome packaging. Curr Top Microbiol Immunol 2003, 277:89-110.
25. Saib A: Non-primate foamy viruses. Curr Top Microbiol Immunol 2003, 277:197-211.
26. Heinkelein M, Dressler M, Jarmy G, Rammling M, Imrich H, Thurow J, Lindemann D, Rethwilm A: Improved primate foamy virus vectors and packaging constructs. J Virol 2002, 76:3774-3783.
27. Heinkelein M, Leurs C, Rammling M, Peters K, Hanenberg H, Rethwilm A: Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol 2002, 76:10069-10073.
28. Peters K, Wiktorowicz T, Heinkelein M, Rethwilm A: RNA and protein requirements for incorporation of the pol protein into foamy virus particles. J Virol 2005, 79:7005-7013.
29. Stirnnagel K, Lüftenegger D, Stange A, Swiersy A, Müllers E, Reh J, Stanke N, Grosse A, Chiantia S, Keller H, Schwille P, Hanenberg H, Zentgraf H, Lindemann D: Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology 2010, 7:45.
30. Swiersy A, Wiek C, Reh J, Zentgraf H, Lindemann D: Orthoretroviral-like Prototype Foamy Virus Gag-Pol expression is compatible with viral replication. Retrovirology 2011, 8:66.
31. Hütter S, Müllers E, Stanke N, Reh J, Lindemann D: Prototype Foamy Virus Protease Activity Is Essential for Intraparticle Reverse Transcription Initiation but Not Absolutely Required for Uncoating upon Host Cell Entry. J Virol 2013, 87:3163-3176.
32. Tobaly-Tapiero J, Bittoun P, Lehmann-Che J, Delelis O, Giron ML, de The H, Saib A: Chromatin tethering of incoming foamy virus by the structural Gag protein. Traffic 2008, 9:1717-1727.
33. Müllers E, Stirnnagel K, Kaulfuss S, Lindemann D: Prototype Foamy Virus Gag Nuclear Localization: a Novel Pathway among Retroviruses. J Virol 2011, 85:9276-9285.
34. Schneider WM, Brzezinski JD, Aiyer S, Malani N, Gyuricza M, Bushman FD, Roth MJ: Viral DNA tethering domains complement replication-defective mutations in the p12 protein of MuLV Gag. Proc Natl Acad Sci U S A 2013, 110:9487-9492.
35. Enssle J, Fischer N, Moebes A, Mauer B, Smola U, Rethwilm A: Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol 1997, 71:7312-7317.
36. Lee EG, Linial ML: Deletion of a Cys-His motif from the Alpharetrovirus nucleocapsid domain reveals late domain mutant-like budding defects. Virology 2006, 347:226-233.
37. Muriaux D, Costes S, Nagashima K, Mirro J, Cho E, Lockett S, Rein A: Role of murine leukemia virus nucleocapsid protein in virus assembly. J Virol 2004, 78:12378-12385.
38. Reh J, Stange A, Götz A, Rönitz M, Grosse A, Lindemann D: An N-terminal domain helical motif of Prototype Foamy Virus Gag with dual functions essential for particle egress and viral infectivity. Retrovirology 2013, 10:45.
39. Cartellieri M, Herchenröder O, Rudolph W, Heinkelein M, Lindemann D, Zentgraf H, Rethwilm A: N-terminal gag domain required for foamy virus particle assembly and export. J Virol 2005, 79:12464-12476.
40. Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J: Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol 1999, 73:8527-8540.
41. Dorfman T, Luban J, Goff SP, Haseltine WA, Gottlinger HG: Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol 1993, 67:6159-6169.
42. Campbell S, Vogt VM: Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol 1995, 69:6487-6497.
43. Zuber G, McDermott J, Karanjia S, Zhao W, Schmid MF, Barklis E: Assembly of retrovirus capsid-nucleocapsid proteins in the presence of membranes or RNA. J Virol 2000, 74:7431-7441.
44. Muriaux D, Mirro J, Harvin D, Rein A: RNA is a structural element in retrovirus particles. Proc Natl Acad Sci U S A 2001, 98:5246-5251.
45. Goldstone DC, Flower TG, Ball NJ, Sanz-Ramos M, Yap MW, Ogrodowicz RW, Stanke N, Reh J, Lindemann D, Stoye JP, Taylor IA: A Unique Spumavirus Gag N-terminal Domain with Functional Properties of Orthoretroviral Matrix and Capsid. PLoS Pathog 2013, 9:e1003376.
46. Fischer N, Heinkelein M, Lindemann D, Enssle J, Baum C, Werder E, Zentgraf H, Müller JG, Rethwilm A: Foamy virus particle formation. J Virol 1998, 72:1610-1615.
47. Baldwin DN, Linial ML: The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol 1998, 72:3658-3665.
48. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP: Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987, 7:379-387.
49. Shooter RA, Gey GO: Studies of the mineral requirements of mammalian cells. Br J Exp Pathol 1952, 33:98-103.
50. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB: Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974, 33:1027-1033.
51. Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M, McClure MO, Rethwilm A: Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 1997, 71:7305-7311.
52. Heinkelein M, Pietschmann T, Jarmy G, Dressler M, Imrich H, Thurow J, Lindemann D, Bock M, Moebes A, Roy J, Herchenröder O, Rethwilm A: Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. Embo J 2000, 19:3436-3445.
53. Hamann MV, Stanke N, Müllers E, Stirnnagel K, Hütter S, Artegiani B: Bragado Alonso S, Calegari F, Lindemann D: Efficient Transient Genetic Manipulation In Vitro and In Vivo by Prototype Foamy Virus-mediated Nonviral RNA Transfer. Mol Ther 2014, 22:1460-1471.
54. Mannigel I, Stange A, Zentgraf H, Lindemann D: Correct capsid assembly mediated by a conserved YXXLGL motif in prototype foamy virus Gag is essential for infectivity and reverse transcription of the viral genome. J Virol 2007, 81:3317-3326.
55. Ho YP, Schnabel V, Swiersy A, Stirnnagel K, Lindemann D: A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors. Mol Ther 2012, 20:1167-1176.
56. Stange A, Lüftenegger D, Reh J, Weissenhorn W, Lindemann D: Subviral particle release determinants of prototype foamy virus. J Virol 2008, 82:9858-9869.
57. Imrich H, Heinkelein M, Herchenröder O, Rethwilm A: Primate foamy virus Pol proteins are imported into the nucleus. J Gen Virol 2000, 81:2941-2947.